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Abstract
AIM: To investigate both whether the risk of gastric 
cancer is associated with the Ile/Val single nucleotide 
polymorphism (SNP) of human epidermal growth factor 
receptor-2 (HER-2 )  transmembrane domain-coding re-
gion at codon 655 and the suggested existence of HER-2  
expression in gastric cancer cases in a Turkish patient 
group. 
METHODS: Polymerase chain reaction (PCR) followed 
by restriction fragment length polymorphism (RFLP) 
strategy was used to analyze the presence of HER-2 SNP 
at codon 655. c-erbB-2 expression pattern was analyzed 
by immunohistochemistry. The results were compared 
between gastric carcinoma group and chronic gastritis 
group, as well as between clinicopathological parameters 
and carcinoma. 
RESULTS: Results showed that Ile/Val genotype ac-
counted for 20% within the Turkish gastric carcinoma 
group, and none in chronic gastritis group, and this ge-
notyping was associated with stage IV gastric cancers 
(P = 0.04). Positive membranous HER-2  immunoreac-
tivity, on the other hand, accounted for 24% within the 
Turkish gastric carcinoma group and none from chronic 
gastritis cases; further, it was correlated with intestinal 
type carcinomas (P = 0.007), and stage III-IV carcino-
mas (P = 0.004). 
CONCLUSION: These observations imply that the tested 
HER-2 SNP may participate in the development and pro-
gression of gastric cancer. Thus, after confirming these 
results with large sample groups, HER-2 codon 655 SNP 
and/or c-erbB-2 overexpression may also be used as a 
poor prognostic indicator for gastric carcinomas.
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INTRODUCTION
Gastric adenocarcinoma is the second leading cause of  
cancer-specific mortality worldwide and efforts intended 
for prevention and early detection of  gastric carcinoma are 
effective and yet important[1]. Despite various treatments 
such as gastrectomy with extensive lymphadenectomy and 
surgery combined with chemotherapy, the control of  gas-
tric cancer at advanced stages is still challenging.
Molecular genetic analyses have indicated that trans-
formation of  normal epithelial cells into a cancer is a 
multi-step process associated with the progressive accumu-
lation of  abnormalities in DNA repair genes, tumor sup-
pressor genes, oncogenes, cellular growth factors, surface 
receptors, and cellular adhesion molecules[2]. Structural and 
functional alterations of  human epidermal growth factor 
receptor-2 (HER-2) also known as c-ErbB-2/neu proto-
oncogene have been reported in different steps of  carcino-
genesis including initiation, promotion and progression[3]. 
HER-2 is a member of  the epidermal growth factor (EGF) 
receptor family located at chromosome 17q21 that encodes 
a 185-kDa transmembrane glycoprotein with tyrosine ki-
nase activity[4-6]. It is localized to the cell membrane and 
binding of  extracellular growth factor ligands to HER-2 
leads to the formation of  dimers with another molecule of  
HER-2 or with HER-1 (EGFr), HER-3 or HER-4. This 
dimerization results in phosphorylation of  tyrosine resi-
dues on the cytoplasmic domain of  the receptor and sub-
sequent activation of  intracellular signaling pathways that 
regulate diverse biologic responses, including proliferation, 
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differentiation, cell motility, and survival[7]. Overexpression 
of c-erbB-2 has frequently been reported in various cancer 
types including breast, ovary, lung, salivary gland, colon, 
prostate and pancreatic and has been suggested to be an 
indicator of  poor prognosis[8,9]. HER-2 DNA amplification 
is suggested to be the principal mechanism of  HER-2/neu 
protein activation and is nearly always accompanied by its 
protein overexpression in breast cancer. It has been also re-
ported c-erbB-2 overexpression in 10% to 38% of  gastric 
cancer cases using immunohistochemical, Southern blot, 
and fluorescent in situ hybridization analyses that suggest 
differences in c-erbB-2 expression among subtypes of  gas-
tric cancer[10-13]. However, controversy continues in terms 
of  correlation between the HER-2 protein expression and 
gastric cancer prognosis. There have been reports cor-
relating the lymph node metastasis and/or liver metastasis 
with HER-2 expression[14-17], whereas others showed no 
correlation between clinicopathologic findings and HER-2 
expression[18,19]. In addition, it has also been shown that 
HER-2 expression is fewer than 10% in diffuse adenocar-
cinomas[16,17]. The use of  trastuzumab, a function blocking 
monoclonal antibody against the extracellular domain of  
HER-2, as a treatment option in HER-2-overexpressing 
advanced breast cancer patients underlines once again the 
importance of  this protein and its downstream signaling 
cascade(s) in the pathogenesis of  above-mentioned can-
cers.
Presence of  a single nucleotide polymorphism (SNP) 
in the transmembrane coding region of  the HER-2 gene 
at codon 655, encoding either isoleucine (Ile: ATC) or 
valine (Val: GTC), has been reported in different cancer 
types[12,13]. Changing the existing isoleucine (Ile: ATC) to 
valine (Val: GTC) at codon 655, suggests an increased di-
merization, autophosphorylation of  HER-2 and tyrosine 
kinase activity, which may cause the transformation of  
cells[16]. Some of  the reports have revealed that the pres-
ence of  Ile/Val SNP is associated with increased risk of  
breast cancer development[20]; on the other hand, others 
have shown that this correlation is controversial[21-24]. One 
reason for these contradictory results might be the sub-
stantial differences in genetic polymorphism in the HER-2 
codon 655 between ethnic groups.
In this study, the frequency of  HER-2 codon 655 
polymorphism, resulting in an A to G transition (Ile655Val) 
and alterations in c-erbB-2 protein expression have been 
investigated in Turkish gastric cancer patients in associa-
tion with the clinicopathologic parameters.
MATERIALS AND METHODS
Materials
The specimens at Pamukkale University Department of  
Pathology archive have been used and paraffin-embedded 
tissues of  25 gastric carcinomas (8 with diffuse type, 16 
with intestinal type, i.e., 5 with well, 4 with moderately, 7 
with poorly differentiated adenocarcinoma, classified ac-
cording to Lauren classification and 1 with adenosquamous 
type) were selected as the study group in this study (Table 1). 
All carcinomas were staged according to UICC criteria, 
graded according to WHO criteria, and histopathologically 
typed according to Lauren classification. Paraffin-embed-
ded tissues of  18 chronic gastritis cases selected from the 
same collection served as the control group.
DNA extraction and mutation analysis
DNA extraction from paraffin-embedded tissues was 
performed using the QIAamp DNA Mini Kit (Qiagen, 
Hilden-Germany) according to the manufacturer’s pro-
tocol. SNP in HER-2 transmembrane segment involving 
codon 655 was analyzed by polymerase chain reaction 
(PCR) followed by restriction fragment length polymor-
phism (RFLP) strategy[25]. The 148 bp transmembrane 
segment of  HER-2 was PCR-amplified using the gene 
specific primers, i.e., forward (HER-2/F) 5’-AGAGCGC-
CAGCCCTCTGACGTCCAT-3’, and reverse (HER-2/R) 
5’-TCCGTTTCCTGCAGCAGTCTCCGCA-3’[25]. All 
PCR amplifications were performed in a total volume of  
50 µL containing 10 µL of  extracted DNA, 20 pmol/L of  
each forward and reverse primer, and 25 µL of  HotStar-
Taq Master Mix [containing 2.5 units of  HotStarTaq DNA 
polymerase, 1 × PCR buffer with 1.5 mmol/L MgCl2, and 
200 µmol/L of  each dNTP (Qiagen, Hilden-Germany)]. 
Thermal cycling conditions for the PCR are as follows: 
initial activation of  HotStarTaq DNA polymerase at 95 ℃ 
for 15 min, followed by 35 cycles of  94 ℃ for 0.5 min, 
62 ℃ for 0.5 min, 72 ℃ for 1 min, and a final extension of  
72 ℃ for 10 min. PCR products were subjected to electro-
phoresis on a 2% ethidium bromide (Et-Br) stained aga-
rose gel and visualized under UV for the control of  their 
specificity and integrity.
For RFLP analysis, 5 µL of  each PCR product was 
digested with BsmAI (New England Biolabs, Ipswich, MA-
USA) at 55 ℃ for 2 h, and enzyme was heat-inactivated at 
80 ℃ for 20 min. BsmAI digestion gave fragments of  116 
bp and 32 bp for the Val (GTC) allele and a single 148 bp 
fragment for the Ile (ATC) allele[11]. Fragments digested 
with BsmAI were subjected to electrophoresis on a 3% 
molecular screening grade agarose gel (Roche Diagnostics, 
GmbH, Mannheim-Germany), stained with Et-Br and vi-
sualized under UV light.
Table 1  Clinicopathological details of gastric 
carcinoma cases
































1 Not Determined: 5 cases were endoscopic biopsy 
samples so cannot be determined.
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Immunohistochemistry
Formalin fixed, paraffin-embedded tumor-rich representa-
tive tissues were used for immunohistochemical staining. 
Reactions were performed with anti-c-erbB-2 polyclonal 
antibody (DAKO, Glostrup-Denmark) using the strep-
tavidin biotin peroxidase method along with DAB as 
chromogen by Ventana-NexES IHC automatic immunos-
tainer. Staining patterns were analyzed semiquantitatively 
and scored in the range of  0 to 3, score 0: Less than 10%; 
score 1: More than 10% of  tumor cells with partial mem-
branous staining; score 2: More than 10% cells with mod-
erate membranous staining; score 3: More than 10% cells 
with strong membranous staining.
Statistical analysis
The data were analyzed by the Chi-Square test. Differences 
at P < 0.05 were considered to be significant. Statistical 
analyses were performed with SSPS software, Version 11.0.
RESULTS
HER-2 PCR-RFLP analysis showed that none of  the 18 
chronic gastritis cases had the SNP in HER-2 gene at co-
don 655 (Figure 1A), whereas 4 of  25 gastric carcinoma 
cases (20%) had the Ile/Val genotype (Figure 1B, Table 2). 
The difference between these two groups were significant 
(P = 0.04). All 4 mutation positive cases were stage IV in 
terms of  clinicopathologic parameters (Table 2). How-
ever, presence of  this SNP did not show any correlation 
with the age, gender, histological type (according to Lau-
ren), serosal invasion, lymph node metastasis, and distant 
metastasis.
Positive membranous c-erbB-2 immunoreactivity 
(scores 2-3), on the other hand, was detected in 6 of  25 
carcinoma cases (24%), i.e., 4 cases with score 2 (16%) 
and 2 cases with score 3 (8%) (Figure 2A and B, Table 2), 
whereas 5 cases showed score 1 staining (20%) and 14 cas-
es showed no staining at all (56%, Table 2). Results from 
chronic gastritis cases revealed no positive membranous 
c-erbB-2 immunoreactivity, i.e., 4 cases had score 1 staining 
(19%) (Figure 2C) and 17 cases had no staining at all (81%). 
When the results from carcinoma group were compared 
with clinicopathologic parameters, positive membranous 
c-erbB-2 immunoreactivity was correlated with intestinal 
type carcinomas (P = 0.007), and stage III-IV carcinomas 
(P = 0.004). However, no correlation with the age, gender, 
serosal invasion, lymph node metastasis, and distant metas-
tasis was observed. 
DISCUSSION
The aim of  this study was to investigate both whether 
the risk of  gastric cancer is associated with the Ile/Val 
SNP of  HER-2 transmembrane domain-coding region at 
codon 655 and the suggested existence of  c-erbB2 expres-
sion in gastric cancer cases in a Turkish patient group. 
Results showed that Ile/Val genotype accounted for 20% 
of  the Turkish gastric carcinoma group (P = 0.04), and 
this genotype was associated with stage IV gastric cancers. 
However, it did not show any correlation with the age, 
gender, histological type (according to Lauren classifica-
tion), serosal invasion, lymph node metastasis, and distant 
metastasis. Positive membranous c-erbB-2 immunoreactiv-
ity, on the other hand, accounted for 24% of  the Turkish 
gastric carcinoma group and it was found to be correlated 
with intestinal type carcinomas (P = 0.007), and stage III-
Table 2  Summary of HER-2 SNP presence and c-erbB-2 expression 











  1 D 4 - 0
  2 D 4 - 0
  3 I 4 + 1
  4 D - 0
  5 D - 0
  6 D 4 - 0
  7 D 3 - 0
  8 D 4 - 0
  9 I 4 - 0
10 I 4 + 3
11 D 3 - 0
12 I 4 - 2
13 I 2 - 1
14 I 4 - 0
15 I 4 - 1
16 I 4 + 0
17 I 1 - 1
18 I 4 + 3
19 I - 1
20 I 4 - 2
21 I 2 - 2
22 I - 0
23 I - 2
24 I 3 - 0
25 Other 4 - 0
D: diffuse type; I: intestinal type; (-): negative; (+): positive.
200 bp 148 bp
(-) M  1  2  3   4  5  6   7  8   9 10 11 12  13 14  15 16 17 18
A
Figure 1  SNP analysis in (A) chronic gastritis group, and (B) gastric carcinoma 
group. The SNP in codon 655 of HER-2 was detected in patients No 3, 10, 16, and 
18 of gastric carcinoma group (*). M, molecular weight marker; (-), negative control 
for PCR; bp, base pair.
M  (-) 16 17  18  19  20  21 22 23  24  25
* *
200 bp 148 bp
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IV carcinomas (P = 0.004). These observations imply that 
the tested HER-2 SNP may participate in the development 
and rapid progression of  gastric cancer. However, further 
larger sample studies particularly containing early stage 
gastric carcinoma patients, are needed to confirm the pres-
ence of  SNP and/or c-erbB-2 overexpression may also be 
used as a poor prognostic indicator for gastric carcinomas.
HER-2 encodes a receptor tyrosine kinase function-
ing as a growth regulatory protein and a cell motility fac-
tor[26]. Alterations of  HER-2 have been implicated in the 
carcinogenesis and are frequently observed in a variety of  
tumors[24, 27-29]. The molecular mechanism of  the associa-
tion between the Ile/Val SNP at codon 655 of  HER-2 
and cancer has not been fully understood; however, it has 
been suggested that Ile/Val SNP at codon 655 of  HER-2 
results in increased dimerization, autophosphorylation of  
HER-2 and tyrosine kinase activity[16], which may cause 
the transformation of  cells. In spite of  initial reports on 
the association of  this SNP with the risk of  a variety of  
cancers, there is still an ongoing debate on this topic. To 
our knowledge, this is the first study in a Turkish gastric 
carcinoma group investigating the existence of  the Ile/Val 
genotype. Although the study group here is small, the 20% 
occurrence rate in this Turkish gastric carcinoma patient 
group is comparable to the reported 21% occurrence rate 
in a Japanese gastric carcinoma group of  212 patients[25]. It 
suggests a significantly increased risk of  gastric cancer de-
velopment. The association of  this genotyping with stage 
IV gastric cancers also supports this finding.
Overexpression of  c-erbB-2, on the other hand, has 
been associated with poor prognosis and shorter overall 
survival[14, 30-32] and may be used as a predictive marker 
for the response to therapy in some cancers[33]. However, 
a controversy also continues in terms of  correlation be-
tween the c-erbB-2 protein expression and gastric cancer 
prognosis. There have been reports correlating the lymph 
node metastasis and/or liver metastasis with c-erbB-2 
expression[14-17], whereas others showed no correlation 
between the clinicopathologic findings and c-erbB-2 ex-
pression[18,19]. Results of  this study also correlate with a 
previous report by Dursun et al[34] in terms of  positive 
membranous c-erbB-2 immunoreactivity within a Turk-
ish gastric carcinoma group. Like suggested previously[34] 
this study has shown association of  positive membranous 
c-erbB-2 immunoreactivity with intestinal type carcino-
mas (P = 0.007), and stage III-IV carcinomas (P = 0.004). 
However, it has to be taken into consideration that both 
studies have worked with small patient groups leading to a 
decreased statistical power to detect a positive association 
of  any kind. Thus, further investigation with a desirable 
study group size is necessary to assess the importance of  
c-erbB-2 expression in gastric carcinomas for the Turkish 
population. Nevertheless, results of  this study suggest in-
creased c-erbB-2 expression may be considered as a poor 
prognostic indicator.
In conclusion, this study suggests that the tested SNP 
in the transmembrane domain-coding region of  HER-2 
could be associated with development of  gastric carci-
noma and may serve as a predictor of  risk of  malignant 
phenotype of  gastric cancer for the Turkish population. 
Although the association of  the HER-2 immunoreactiv-
ity with clinicopathologic characteristics, especially with 
intestinal type carcinomas, is also suggested, this has to be 
confirmed with a larger sample size.
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